<HashMap><database>biostudies-literature</database><scores/><additional><submitter>LaBella D</submitter><funding>Foundation for the National Institutes of Health</funding><funding>Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)</funding><pagination>306</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12948943</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(1)</volume><pubmed_abstract>Meningiomas are the most common primary intracranial tumors, frequently requiring radiotherapy as a part of management. Effective radiotherapy planning for meningiomas necessitates accurate and consistent segmentation of target volumes on MRI, a process that is complex, labor-intensive, and dependent on expert expertise. The 2024 Brain Tumor Segmentation Challenge Meningioma Radiotherapy (BraTS-MEN-RT) Dataset addresses this problem by providing the largest multi-institutional collection of systematically annotated radiotherapy planning MRIs for meningiomas. Publicly accessible, this dataset comprises 570 radiotherapy planning 3D T1-weighted post-contrast MRIs at native resolutions, with 500 cases featuring expert-annotated gross tumor volumes (GTV). Annotations follow standardized radioth</pubmed_abstract><journal>Scientific data</journal><pubmed_title>The 2024 Brain Tumor Segmentation Challenge Meningioma Radiotherapy (BraTS-MEN-RT) dataset.</pubmed_title><pmcid>PMC12948943</pmcid><funding_grant_id>NCI/ITCR U01CA242871</funding_grant_id><funding_grant_id>U24CA279629</funding_grant_id><funding_grant_id>NCI K08CA256045</funding_grant_id><funding_grant_id>U01CA242871</funding_grant_id><pubmed_authors>Wang C</pubmed_authors><pubmed_authors>Mix M</pubmed_authors><pubmed_authors>Halasz LM</pubmed_authors><pubmed_authors>Moassefi M</pubmed_authors><pubmed_authors>Rudie JD</pubmed_authors><pubmed_authors>Al-Salihi O</pubmed_authors><pubmed_authors>Saluja R</pubmed_authors><pubmed_authors>Taylor P</pubmed_authors><pubmed_authors>de Verdier MC</pubmed_authors><pubmed_authors>Huang R</pubmed_authors><pubmed_authors>Barfoot T</pubmed_authors><pubmed_authors>McBurney-Lin S</pubmed_authors><pubmed_authors>Schumacher K</pubmed_authors><pubmed_authors>Mullikin TC</pubmed_authors><pubmed_authors>Vercauteren T</pubmed_authors><pubmed_authors>Gagnon L</pubmed_authors><pubmed_authors>Villanueva-Meyer J</pubmed_authors><pubmed_authors>Floyd SR</pubmed_authors><pubmed_authors>Ivory M</pubmed_authors><pubmed_authors>Menze B</pubmed_authors><pubmed_authors>Bakas S</pubmed_authors><pubmed_authors>Sachdev S</pubmed_authors><pubmed_authors>Kofler F</pubmed_authors><pubmed_authors>Anwar SM</pubmed_authors><pubmed_authors>Shapey J</pubmed_authors><pubmed_authors>Nada A</pubmed_authors><pubmed_authors>Anazodo U</pubmed_authors><pubmed_authors>Nedelec P</pubmed_authors><pubmed_authors>Bagci U</pubmed_authors><pubmed_authors>Warman P</pubmed_authors><pubmed_authors>Maleki N</pubmed_authors><pubmed_authors>Vollmuth P</pubmed_authors><pubmed_authors>Raleigh DR</pubmed_authors><pubmed_authors>Seibert TM</pubmed_authors><pubmed_authors>Faghani S</pubmed_authors><pubmed_authors>Abayazeed AH</pubmed_authors><pubmed_authors>Kirkpatrick JP</pubmed_authors><pubmed_authors>Sheller M</pubmed_authors><pubmed_authors>Baid U</pubmed_authors><pubmed_authors>Reitman ZJ</pubmed_authors><pubmed_authors>Adewole M</pubmed_authors><pubmed_authors>Kazerooni AF</pubmed_authors><pubmed_authors>Karargyris A</pubmed_authors><pubmed_authors>Jakab A</pubmed_authors><pubmed_authors>Moawad AW</pubmed_authors><pubmed_authors>Kassem H</pubmed_authors><pubmed_authors>Shiue K</pubmed_authors><pubmed_authors>Albrecht J</pubmed_authors><pubmed_authors>Linguraru MG</pubmed_authors><pubmed_authors>Aboian M</pubmed_authors><pubmed_authors>Conte GM</pubmed_authors><pubmed_authors>Puett C</pubmed_authors><pubmed_authors>Chung V</pubmed_authors><pubmed_authors>Chai R</pubmed_authors><pubmed_authors>Tahon NH</pubmed_authors><pubmed_authors>Hongwei B L</pubmed_authors><pubmed_authors>Pati S</pubmed_authors><pubmed_authors>Aristizabal A</pubmed_authors><pubmed_authors>Rauschecker AM</pubmed_authors><pubmed_authors>Lohmann P</pubmed_authors><pubmed_authors>Pease MW</pubmed_authors><pubmed_authors>Schwarz CG</pubmed_authors><pubmed_authors>LaBella D</pubmed_authors><pubmed_authors>Farid N</pubmed_authors><pubmed_authors>Calabrese E</pubmed_authors><pubmed_authors>Chia K</pubmed_authors><pubmed_authors>Leu J</pubmed_authors><pubmed_authors>Leu K</pubmed_authors><pubmed_authors>Velichko Y</pubmed_authors><pubmed_authors>Wiestler B</pubmed_authors><pubmed_authors>Vaios EJ</pubmed_authors><pubmed_authors>Hattangadi-Gluth JA</pubmed_authors></additional><is_claimable>false</is_claimable><name>The 2024 Brain Tumor Segmentation Challenge Meningioma Radiotherapy (BraTS-MEN-RT) dataset.</name><description>Meningiomas are the most common primary intracranial tumors, frequently requiring radiotherapy as a part of management. Effective radiotherapy planning for meningiomas necessitates accurate and consistent segmentation of target volumes on MRI, a process that is complex, labor-intensive, and dependent on expert expertise. The 2024 Brain Tumor Segmentation Challenge Meningioma Radiotherapy (BraTS-MEN-RT) Dataset addresses this problem by providing the largest multi-institutional collection of systematically annotated radiotherapy planning MRIs for meningiomas. Publicly accessible, this dataset comprises 570 radiotherapy planning 3D T1-weighted post-contrast MRIs at native resolutions, with 500 cases featuring expert-annotated gross tumor volumes (GTV). Annotations follow standardized radioth</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-07-16T23:24:03.006Z</modification><creation>2026-07-12T03:11:11.408Z</creation></dates><accession>S-EPMC12948943</accession><cross_references><pubmed>41593091</pubmed><doi>10.1038/s41597-026-06649-x</doi></cross_references></HashMap>